OrbiMed’s IQVIA IQV Stock Holding History

OrbiMed’s Portfolio IQV Stock Details IQV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-175,000	Closed	-$24.8M	–	154
2020 Q2	$24.8M	Hold	175,000	–	–	0.35%	69
2020 Q1	$18.9M	Hold	175,000	–	–	0.32%	68
2019 Q4	$27M	Hold	175,000	–	–	0.39%	58
2019 Q3	$26.1M	Buy	+175,000	New	+$27.2M	0.5%	52
2013 Q4	–	Sell	-440,000	Closed	-$19.7M	–	131
2013 Q3	$19.7M	Hold	440,000	–	–	0.35%	56
2013 Q2	$18.7M	Buy	+440,000	New	+$19.3M	0.4%	51

Other funds holding IQV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Longview Partners St Peter Port, Guernsey $6.16B AUM 3.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SCM

Steadfast Capital Management New York $3.26B AUM 36.54% 1-Year Est. Return

OrbiMed's IQV Position: Q3 2020 in Review

OrbiMed sold out of IQVIA (IQV) in Q3 2020, closing a stake of 175,000 shares — an estimated $24.8M sold.

OrbiMed first reported a position in IQV in Q2 2013 and held it in 6 quarters. The position peaked at $27M in Q4 2019. 698 funds tracked by Wall St. Rank hold IQV as of Q3 2020.

OrbiMed reported no remaining IQVIA position as of Q3 2020 after selling out during the quarter.
OrbiMed sold 175,000 IQVIA shares in Q3 2020, an estimated $24.8M.
OrbiMed first reported a position in IQVIA in Q2 2013 and held it in 6 quarters.
OrbiMed's IQVIA position peaked at $27M in Q4 2019.
698 funds tracked by Wall St. Rank held IQVIA as of Q3 2020.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.